The safety profile, and more specifically, the incidence of severe peripheral neuropathy, infections, or IRs was favorable to this combination compared with existing data of anti-CD38-based triplets or quadruplets in the frontline setting in the same patient population. The gene discussed is CD38; the disease is infection.